Buy Johnson & Johnson
Amount
Latest price
$150.88
(£1.00 = $1.349)
Number of shares (est.)
0
Start investing today
Open an investment account in Emma and enjoy commission free stock trading. Capital at risk, other charges apply.
Metrics
Market Cap
$362.667B
P/E ratio
16.77
EPS
$8.988
Beta
0.41
Dividend rate
$4.96
Dividend yield
3.29%
About
Johnson & Johnson and its subsidiaries are engaged in the research and development, manufacture, and sale of a range of products in the healthcare field. The Company's primary focus is products related to human health and well-being. The Company operates through two segments: Innovative Medicine and MedTech. The Innovative Medicine segment is focused on various therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, and cardiovascular and metabolism. Medicines in this segment are distributed directly to retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. The MedTech segment includes a broad portfolio of products used in the orthopedic, surgery, cardiovascular, and vision fields. These products are distributed to wholesalers, hospitals and retailers, and used principally in the professional fields by physicians, nurses, hospitals, eyecare professionals, and clinics.
CEO
Mr. Joaquin Boix Duato
Employees
138,100
Sector
Health
Company HQ
NEW BRUNSWICK, United States of America
Website
News
Johnson & Johnson Hit With $8M Verdict in Massachusetts Mesothelioma Talc Lawsuit
BOSTON--(BUSINESS WIRE)--A Suffolk County jury has awarded $8 million in favor of Janice Paluzzi, a Massachusetts woman who developed mesothelioma after decades of using Johnson & Johnson's (NYSE:JNJ) talcum powder products. The jury found the pharmaceutical giant liable for negligence and breach of warranty, concluding that the company's asbestos-contaminated talcum powder products caused Paluzzi's terminal cancer. During the trial, the Dean Omar Branham Shirley legal team, which represent.
© 2025 Emma Technologies Ltd. All Rights Reserved.
Emma is registered and incorporated in England and Wales.
Emma Technologies Ltd is an appointed representative of RiskSave Technologies Ltd, which is authorised and regulated by the Financial Conduct Authority (FRN 775330).
Payment services (Non MIFID or Deposit related products) for Emma Technologies Ltd are provided by The Currency Cloud Limited. Registered in England No. 06323311. Registered Office: Stewardship Building 1st Floor, 12 Steward Street London E1 6FQ. The Currency Cloud Limited is authorised by the Financial Conduct Authority under the Electronic Money Regulations 2011 for the issuing of electronic money (FRN: 900199). For more detail on how your money is protected please see here. You can also find Currency Cloud's Terms of Use here.
Emma Technologies is an Introducer Appointed Representative of Quint Group Limited and not a lender. Quint Group Limited is authorised and regulated by the Financial Conduct Authority (Firm Reference Number 669450). Monevo Limited is an Appointed Representative of TransUnion International UK Limited. TransUnion is authorised and regulated by the Financial Conduct Authority (Firm Reference Number 737740). Emma Technologies introduces customers first to Quint Group Limited, as a licensed credit broker, who then refers on to Monevo Limited.
Emma is registered with the Financial Conduct Authority under the Payment Services Regulations 2017 for the provision of payment services.
Financial Conduct Authority Reg Nr: 794952.
Company Registration Number: 10578464.
Data Protection Registration Number: ZA241546.
All testimonials, reviews, opinions or case studies presented on our website may not be indicative of all customers. Results may vary and customers agree to proceed at their own risk.
Resources: Cancel subscriptions, Cashback offers, Who charged me, Rent Reporting, Budgeting, Investment universe, Emma vs Moneyhub.
Featured cashback offers: Samsung, SimplyCook, NordVPN, Audible, M&S Homeware.